Strong evidence of a cardiovascular risk reduction benefit of GLP‐1 RAs in people with T2D has accumulated with data from large cardiovascular outcomes trials (CVOT) collectively showing a significant relative risk reduction of 14% for the 3‐component MACE composite outcome (major cardiovascular adverse events, comprising cardiovascular death, myocardial infarction, and non‐fatal stroke) (Sattar et al., 2021). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.